Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamil Musilek

Showing results (31-40 of 199) with videos related to

Pageof 20
Sort By:
Archives of Toxicology|August 29, 2023
Strategies for enhanced bioavailability of oxime reactivators in the central nervous systemEliska Prchalova, Zuzana Kohoutova, Karolina Knittelova, et al.
Chemical Research in Toxicology|December 24, 2009
In silico pharmacophore model for tabun-inhibited acetylcholinesterase reactivators: a study of their stereoelectronic propertiesApurba K Bhattacharjee, Kamil Kuca, Kamil Musilek, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesteraseKamil Musilek, Kamil Kuca, Daniel Jun, et al.
Basic & Clinical Pharmacology & Toxicology|September 17, 2014
A comparison of the reactivating and therapeutic efficacy of two newly developed oximes (k727 and k733) with oxime k203 and trimedoxime in tabun-poisoned rats and miceJiri Kassa, Vendula Sepsova, Martina Tumova, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|October 3, 2015
Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited AcetylcholinesteraseKamil Musilek, Jan Hambalek, Ondrej Holas, et al.
Toxicology Mechanisms and Methods|April 21, 2015
A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K727, K733) with the oxime HI-6 and obidoxime in sarin-poisoned rats and miceJiri Kassa, Vendula Sepsova, Lenka Matouskova, et al.
Medicinal Research Reviews|September 16, 2022
Recent advances in dopamine D<sub>2</sub> receptor ligands in the treatment of neuropsychiatric disordersRadomir Juza, Kamil Musilek, Eva Mezeiova, et al.
Medicinal Research Reviews|May 16, 2022
Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseasesAnnamaria Haleckova, Ondrej Benek, Lucie Zemanová, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|March 9, 2010
Reactivation potency of the acetylcholinesterase reactivator obidoxime is limitedKamil Kuca, Kamil Musilek, Miroslav Pohanka, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|March 6, 2012
An in silico stereo-electronic comparison of conventional pyridinium oximes and K-oximes for organophosphate (OP) poisoningApurba K Bhattacharjee, Kamil Kuca, Kamil Musilek, et al.
Pageof 20

Showing results (31-40 of 199) with videos related to

Sort By:
Pageof 20
Archives of Toxicology|August 29, 2023
Strategies for enhanced bioavailability of oxime reactivators in the central nervous systemEliska Prchalova, Zuzana Kohoutova, Karolina Knittelova, et al.
Chemical Research in Toxicology|December 24, 2009
In silico pharmacophore model for tabun-inhibited acetylcholinesterase reactivators: a study of their stereoelectronic propertiesApurba K Bhattacharjee, Kamil Kuca, Kamil Musilek, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesteraseKamil Musilek, Kamil Kuca, Daniel Jun, et al.
Basic & Clinical Pharmacology & Toxicology|September 17, 2014
A comparison of the reactivating and therapeutic efficacy of two newly developed oximes (k727 and k733) with oxime k203 and trimedoxime in tabun-poisoned rats and miceJiri Kassa, Vendula Sepsova, Martina Tumova, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|October 3, 2015
Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited AcetylcholinesteraseKamil Musilek, Jan Hambalek, Ondrej Holas, et al.
Toxicology Mechanisms and Methods|April 21, 2015
A comparison of the reactivating and therapeutic efficacy of two novel bispyridinium oximes (K727, K733) with the oxime HI-6 and obidoxime in sarin-poisoned rats and miceJiri Kassa, Vendula Sepsova, Lenka Matouskova, et al.
Medicinal Research Reviews|September 16, 2022
Recent advances in dopamine D<sub>2</sub> receptor ligands in the treatment of neuropsychiatric disordersRadomir Juza, Kamil Musilek, Eva Mezeiova, et al.
Medicinal Research Reviews|May 16, 2022
Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseasesAnnamaria Haleckova, Ondrej Benek, Lucie Zemanová, et al.
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia|March 9, 2010
Reactivation potency of the acetylcholinesterase reactivator obidoxime is limitedKamil Kuca, Kamil Musilek, Miroslav Pohanka, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|March 6, 2012
An in silico stereo-electronic comparison of conventional pyridinium oximes and K-oximes for organophosphate (OP) poisoningApurba K Bhattacharjee, Kamil Kuca, Kamil Musilek, et al.
Pageof 20